Braveheart Bio's Hengrui-licensed cardiac drug scores second clinical win
Braveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same condition in which Cytokinetics recently scored a
May 11, 2026 09:42 AM EDT R&D Braveheart Bio's Hengrui-licensed cardiac drug scores second clinical win Elizabeth Cairns Senior biopharma journalist Braveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that